# US 2022/0033892 A1 · REAGENTS FOR DETECTING ALU ELEMENTS IN CELL-FREE DNA (cfDNA)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033892 A1
- Document ID: US20220033892A1
- Status: Published application
- Kind: A1
- Application number: 17/498,489
- Filed: 2021-10-11
- Published: 2022-02-03
- Earliest claimed: 2016-08-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Minnie M. Sarwal; Tara K. Sigdel; Joshua Y. Yang
- Web page: https://patentgrep.com/patent/US20220033892A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6853: using modified primers or templates
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6827: {Total protein determination, e.g. albumin in urine}
- G01N 33/6839: {involving dyes, e.g. Coomassie blue, bromcresol green}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 33/70: involving creatine or creatinine
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein is the use of measurements of cell-free DNA, protein, and/or metabolite found in biofluid (e.g., urine) for identifying and treating organ injury. Provided herein are methods and compositions for monitoring, detecting, quantifying, and treating kidney injury in subjects suffering from or suspected of having an altered renal status by measuring amounts of cfDNA and one or more other markers, such as inflammation markers, apoptosis markers, protein, and DNA methylation.

## Claims

### Claim 1

A reaction mixture comprising:
i) non-amplified cell-free DNA (cfDNA) extracted from a urine sample; and
ii) a nucleic acid probe having a 3′ end and a 5′ end, wherein the nucleic acid probe is complementary to at least 20 contiguous nucleotides of SEQ ID NO:1 and wherein the 3′ end and/or the 5′ end is covalently ligated to at least one detectable moiety.

### Claim 2 (depends on 1)

The reaction mixture of claim 1, wherein the detectable moiety is a fluorescent molecule.

### Claim 3 (depends on 1)

The reaction mixture of claim 1, wherein the detectable moiety is biotin.

### Claim 4 (depends on 3)

The reaction mixture of claim 3, wherein the reaction mixture further comprises a streptavidin-linked signal-producing agent.

### Claim 5 (depends on 4)

The reaction mixture of claim 4, wherein the streptavidin-linked signal-producing agent produces chemiluminescence, color, or fluorescence.

### Claim 6 (depends on 1)

The reaction mixture of claim 1, wherein the detectable moiety is fluorescein or digoxigenin (DIG).

### Claim 7 (depends on 6)

The reaction mixture of claim 6, wherein the fluorescein or digoxigenin (DIG) is conjugated to horseradish peroxidase (HRP).

### Claim 8 (depends on 1)

The reaction mixture of claim 1, wherein the 3′ end or the 5′ end of the nucleic acid probe is covalently linked to at least two detectable moieties.

### Claim 9 (depends on 1)

The reaction mixture of claim 1, wherein the 3′ and the 5′ ends of the nucleic acid probe are covalently linked to at least two detectable moiety.

### Claim 10 (depends on 1)

The reaction mixture of claim 1, wherein the 3′ end or the 5′ end of the nucleic acid probe is covalently linked to at least three detectable moieties.

### Claim 11 (depends on 1)

The reaction mixture of claim 1, wherein the 3′ and the 5′ ends of the nucleic acid probe are covalently linked to at least three detectable moieties.

### Claim 12 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to 81 nucleotides of SEQ ID NO:1.

### Claim 13 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 20-292 contiguous nucleotides of SEQ ID NO:1.

### Claim 14 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 20-180 contiguous nucleotides of SEQ ID NO:1.

### Claim 15 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 50-150 contiguous nucleotides of SEQ ID NO:1.

### Claim 16 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 70-100 contiguous nucleotides of SEQ ID NO:1.

### Claim 17 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 80-90 contiguous nucleotides of SEQ ID NO:1.

### Claim 18 (depends on 1)

The reaction mixture of claim 1, wherein the nucleic acid probe is complementary to at least 20-300 contiguous nucleotides to SEQ ID NO: 1.

### Claim 19 (depends on 1)

The reaction mixture of claim 1, wherein the urine sample is from a human who has received a kidney transplant.

### Claim 20 (depends on 19)

The reaction mixture of claim 19, wherein the urine sample is taken 0-400 days, or 10-100 days, or 20-50 days, from the date the human received the kidney transplant.

### Claim 21 (depends on 19)

The reaction mixture of claim 19, wherein the urine sample is taken over the lifetime of the human from the date of the human received the kidney transplant.

### Claim 22 (depends on 1)

A method of detecting Alu copy number in cell-free DNA (cfDNA) in a urine sample, the method comprising:
forming a reaction mixture according to claim 1; and
quantifying the amount of cfDNA hybridized to the nucleic acid probe, thereby detecting Alu copy number in cfDNA in the urine sample.
